TROPION-Lung01 Study Design and Baseline demographics
62 patients treated
BEGONIA Arm 7: Dato-DXd + Durvalumab
Disposition and Baseline Characteristics
33 (53%) discontinued treatment
(1 or more reasons may have been reported)
26 (42%) disease progressiona
10 (16%) due to an adverse eventb
4 (7%) patient decisiona
29 (47%) treatment ongoing
Median follow-up: 11.7 (range, 2-20) months
Characteristic
Age, median (range), years
No prior treatment, n (%)
Prior treatments for early-stage disease, n (%)
Radiotherapy
Cytotoxic chemotherapy
Taxane
Anthracycline
Platinum compound
Dato-DXd + D
N=62
53 (31-74)
26 (42)
30 (48)
33 (53)
26 (42)
29 (47)
9 (15)
10 (16)
1 (2)
Targeted therapy
37 (60)
Visceral metastases, n (%)
42 (68)
Lymph node metastases, n (%)
PD-L1 expression, dn (%)
7 (11)
High (TAP ≥10%)
54 (87)
Low (TAP <10%)
Unknown/Missing
1 (2)
Hormonal therapy
*Discontinued all study drugs. "Discontinued any study drug. "Defined as liver/hepatic and/or respiratory metastases. *PD-L1 expression was assessed by immunohistochemistry using the VENTANA PD-L1 (SP263) Assay, and expression was defined as the percentage of the tumour area populated by
tumour or immune cells with membranous staining (TAP). A sample was considered PD-L1 high if it had ≥10% TAPPD-L1 expression.
Dato-DXd, datopotamab deruxtecan; D, durvalumab; PD-L1, programmed cell death ligand-1; TAP, tumour area positivity.
Data cutoff: 02 Feb 2023
Daiichi-Sankyo
38View entire presentation